{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T13:20:22Z","timestamp":1783516822069,"version":"3.55.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,11,4]],"date-time":"2016-11-04T00:00:00Z","timestamp":1478217600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2016,11,4]],"date-time":"2016-11-04T00:00:00Z","timestamp":1478217600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R21 CA186086"],"award-info":[{"award-number":["R21 CA186086"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R21 CA186086"],"award-info":[{"award-number":["R21 CA186086"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1007\/s10549-016-4039-x","type":"journal-article","created":{"date-parts":[[2016,11,4]],"date-time":"2016-11-04T05:03:37Z","timestamp":1478235817000},"page":"153-160","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":49,"title":["A model for individualized risk prediction of contralateral breast cancer"],"prefix":"10.1007","volume":"161","author":[{"given":"Marzana","family":"Chowdhury","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Euhus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracy","family":"Onega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swati","family":"Biswas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pankaj K.","family":"Choudhary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,11,4]]},"reference":[{"key":"4039_CR1","doi-asserted-by":"publisher","first-page":"5203","DOI":"10.1200\/JCO.2007.12.3141","volume":"25","author":"TM Tuttle","year":"2007","unstructured":"Tuttle TM, Habermann EB, Grund EH et al (2007) Increasing use of contralateral prophylactic mastectomy for breast cancer patients: a trend toward more aggressive surgical treatment. J Clin Oncol 25:5203\u20135209","journal-title":"J Clin Oncol"},{"key":"4039_CR2","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1200\/JCO.2008.20.1681","volume":"27","author":"TM Tuttle","year":"2009","unstructured":"Tuttle TM, Jarosek S, Habermann EB et al (2009) Increasing rates of contralateral prophylactic mastectomy among patients with ductal carcinoma in situ. J Clin Oncol 27:1362\u20131367","journal-title":"J Clin Oncol"},{"key":"4039_CR3","doi-asserted-by":"publisher","first-page":"2158","DOI":"10.1200\/JCO.2010.29.4041","volume":"29","author":"TA King","year":"2011","unstructured":"King TA, Sakr R, Patil S et al (2011) Clinical management factors contribute to the decision for contralateral prophylactic mastectomy. J Clin Oncol 29:2158\u20132164","journal-title":"J Clin Oncol"},{"key":"4039_CR4","doi-asserted-by":"publisher","first-page":"2554","DOI":"10.1245\/s10434-010-1091-3","volume":"17","author":"K Yao","year":"2010","unstructured":"Yao K, Stewart AK, Winchester DJ, Winchester DP (2010) Trends in contralateral prophylactic mastectomy for unilateral cancer: a report from the National Cancer Data Base, 1998\u20132007. Ann Surg Oncol 17:2554\u20132562","journal-title":"Ann Surg Oncol"},{"key":"4039_CR5","doi-asserted-by":"publisher","first-page":"4082","DOI":"10.1200\/JCO.2008.19.4225","volume":"27","author":"R Katipamula","year":"2009","unstructured":"Katipamula R, Degnim AC, Hoskin T et al (2009) Trends in mastectomy rates at the Mayo Clinic Rochester: effect of surgical year and preoperative magnetic resonance imaging. J Clin Oncol 27:4082\u20134088","journal-title":"J Clin Oncol"},{"key":"4039_CR6","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0000000000001698","author":"SM Wong","year":"2016","unstructured":"Wong SM, Freedman RA, Sagara Y et al (2016) Growing use of contralateral prophylactic mastectomy despite no improvement in long-term survival for invasive breast cancer. Ann Surg. doi:\n                    10.1097\/SLA.0000000000001698","journal-title":"Ann Surg"},{"key":"4039_CR7","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1200\/JCO.2010.32.7395","volume":"29","author":"HB Nichols","year":"2011","unstructured":"Nichols HB, Berrington de Gonzalez A, Lacey JV et al (2011) Declining incidence of contralateral breast cancer in the United States from 1975 to 2006. J Clin Oncol 29:1564\u20131569","journal-title":"J Clin Oncol"},{"key":"4039_CR8","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/S1470-2045(07)70385-6","volume":"9","author":"Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists\u2019 Group","year":"2008","unstructured":"Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists\u2019 Group (2008) Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 9:45\u201353","journal-title":"Lancet Oncol"},{"key":"4039_CR9","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1016\/S0140-6736(05)66544-0","volume":"365","author":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG)","year":"2005","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687\u20131717","journal-title":"Lancet"},{"key":"4039_CR10","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1016\/S1470-2045(10)70257-6","volume":"11","author":"J Cuzick","year":"2010","unstructured":"Cuzick J, Sestak I, Baum M et al (2010) Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol 11:1135\u20131141","journal-title":"Lancet Oncol"},{"key":"4039_CR11","unstructured":"Uyeno L, Behrendt, Vito C (2012) Contralateral breast cancer: impact on survival after unilateral breast cancer is stage-dependent. In: ASCO breast cancer symposium abstract 69"},{"key":"4039_CR12","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1093\/jnci\/djm267","volume":"100","author":"L Bertelsen","year":"2008","unstructured":"Bertelsen L, Bernstein L, Olsen JH et al (2008) Effect of systemic adjuvant treatment on risk for contralateral breast cancer in the Women\u2019s Environment, Cancer and Radiation Epidemiology Study. J Natl Cancer Inst 100:32\u201340","journal-title":"J Natl Cancer Inst"},{"key":"4039_CR13","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1093\/jnci\/djp181","volume":"101","author":"AW Kurian","year":"2009","unstructured":"Kurian AW, McClure LA, John EM et al (2009) Second primary breast cancer occurrence according to hormone receptor status. J Natl Cancer Inst 101:1058\u20131065","journal-title":"J Natl Cancer Inst"},{"key":"4039_CR14","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1634\/theoncologist.2011-0022","volume":"16","author":"AM Brewster","year":"2011","unstructured":"Brewster AM, Parker PA (2011) Current knowledge on contralateral prophylactic mastectomy among women with sporadic breast cancer. Oncologist 16:935\u2013941","journal-title":"Oncologist"},{"key":"4039_CR15","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s10549-010-1137-z","volume":"127","author":"C Bouchardy","year":"2011","unstructured":"Bouchardy C, Benhamou S, Fioretta G et al (2011) Risk of second breast cancer according to estrogen receptor status and family history. Breast Cancer Res Treat 127:233\u2013241","journal-title":"Breast Cancer Res Treat"},{"key":"4039_CR16","doi-asserted-by":"publisher","first-page":"2132","DOI":"10.1200\/JCO.2010.33.4482","volume":"29","author":"SA Khan","year":"2011","unstructured":"Khan SA (2011) Contralateral prophylactic mastectomy: What do we know and what do our patients know? J Clin Oncol 29:2132\u20132135","journal-title":"J Clin Oncol"},{"key":"4039_CR17","doi-asserted-by":"publisher","first-page":"e262","DOI":"10.1016\/S1470-2045(13)70047-0","volume":"14","author":"JA Murphy","year":"2013","unstructured":"Murphy JA, Milner TD, O\u2019Donoghue JM (2013) Contralateral risk-reducing mastectomy in sporadic breast cancer. Lancet Oncol 14:e262\u2013e269","journal-title":"Lancet Oncol"},{"key":"4039_CR18","first-page":"855","volume":"8","author":"Y Chen","year":"1999","unstructured":"Chen Y, Thompson W, Semenciw R, Mao Y (1999) Epidemiology of contralateral breast cancer. Cancer Epidemiol Biomark Prev 8:855\u2013861","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"4039_CR19","doi-asserted-by":"publisher","first-page":"5887","DOI":"10.1200\/JCO.2008.19.9430","volume":"27","author":"MK Graeser","year":"2009","unstructured":"Graeser MK, Engel C, Rhiem K et al (2009) Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 27:5887\u20135892","journal-title":"J Clin Oncol"},{"key":"4039_CR20","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1007\/BF00052945","volume":"7","author":"LS Cook","year":"1996","unstructured":"Cook LS, White E, Schwartz SM et al (1996) A population-based study of contralateral breast cancer following a first primary breast cancer (Washington, United States). Cancer Causes Control 7:382\u2013390","journal-title":"Cancer Causes Control"},{"key":"4039_CR21","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1016\/S0140-6736(02)08434-9","volume":"359","author":"BG Haffty","year":"2002","unstructured":"Haffty BG, Harrold E, Khan AJ et al (2002) Outcome of conservatively managed early-onset breast cancer by BRCA1\/2 status. Lancet 359:1471\u20131477","journal-title":"Lancet"},{"key":"4039_CR22","doi-asserted-by":"publisher","first-page":"R156","DOI":"10.1186\/bcr3369","volume":"14","author":"K Rhiem","year":"2012","unstructured":"Rhiem K, Engel C, Graeser M et al (2012) The risk of contralateral breast cancer in patients from BRCA1\/2 negative high risk families as compared to patients from BRCA1 or BRCA2 positive families: a retrospective cohort study. Breast Cancer Res 14:R156","journal-title":"Breast Cancer Res"},{"key":"4039_CR23","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1200\/JCO.2012.43.2013","volume":"31","author":"AS Reiner","year":"2013","unstructured":"Reiner AS, John EM, Brooks JD et al (2013) Risk of asynchronous contralateral breast cancer in noncarriers of BRCA1 and BRCA2 mutations with a family history of breast cancer: a report from the Women\u2019s Environmental Cancer and Radiation Epidemiology Study. J Clin Oncol 31:433\u2013439","journal-title":"J Clin Oncol"},{"key":"4039_CR24","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/bjc.1984.12","volume":"49","author":"TG Hislop","year":"1984","unstructured":"Hislop TG, Elwood JM, Coldman AJ et al (1984) Second primary cancers of the breast: incidence and risk factors. Br J Cancer 49:79\u201385","journal-title":"Br J Cancer"},{"key":"4039_CR25","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s10549-007-9709-2","volume":"110","author":"M Schaapveld","year":"2008","unstructured":"Schaapveld M, Visser O, Louwman WJ et al (2008) The impact of adjuvant therapy on contralateral breast cancer risk and the prognostic significance of contralateral breast cancer: a population based study in the Netherlands. Breast Cancer Res Treat 110:189\u2013197","journal-title":"Breast Cancer Res Treat"},{"key":"4039_CR26","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1007\/s10549-012-2183-5","volume":"135","author":"BS Saltzman","year":"2012","unstructured":"Saltzman BS, Malone KE, McDougall JA et al (2012) Estrogen receptor, progesterone receptor, and HER2-neu expression in first primary breast cancers and risk of second primary contralateral breast cancer. Breast Cancer Res Treat 135:849\u2013855","journal-title":"Breast Cancer Res Treat"},{"issue":"18","key":"4039_CR27","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1093\/jnci\/87.18.1359","volume":"87","author":"LS Cook","year":"1995","unstructured":"Cook LS, Weiss NS, Schwartz SM et al (1995) Population-based study of tamoxifen therapy and subsequent ovarian, endometrial, and breast cancers. J Natl Cancer Inst 87:1359\u20131364","journal-title":"JNCI J Natl Cancer Inst"},{"key":"4039_CR28","doi-asserted-by":"publisher","first-page":"4275","DOI":"10.1200\/JCO.2005.10.080","volume":"23","author":"LJ Herrinton","year":"2005","unstructured":"Herrinton LJ, Barlow WE, Yu O et al (2005) Efficacy of prophylactic mastectomy in women with unilateral breast cancer: a cancer research network project. J Clin Oncol 23:4275\u20134286","journal-title":"J Clin Oncol"},{"key":"4039_CR29","doi-asserted-by":"publisher","first-page":"3129","DOI":"10.1245\/s10434-011-1914-x","volume":"18","author":"A Abbott","year":"2011","unstructured":"Abbott A, Rueth N, Pappas-Varco S et al (2011) Perceptions of contralateral breast cancer: an overestimation of risk. Ann Surg Oncol 18:3129\u20133136","journal-title":"Ann Surg Oncol"},{"key":"4039_CR30","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1093\/jnci\/94.20.1564","volume":"94","author":"KA Metcalfe","year":"2002","unstructured":"Metcalfe KA, Narod SA (2002) Breast cancer risk perception among women who have undergone prophylactic bilateral mastectomy. J Natl Cancer Inst 94:1564\u20131569","journal-title":"J Natl Cancer Inst"},{"key":"4039_CR31","doi-asserted-by":"crossref","unstructured":"Lostumbo L, Carbine N, Wallace J, Ezzo J (2004) Prophylactic mastectomy for the prevention of breast cancer. Cochrane Database Syst Rev (4):CD002748","DOI":"10.1002\/14651858.CD002748.pub2"},{"key":"4039_CR32","doi-asserted-by":"crossref","unstructured":"Lostumbo L, Carbine NE, Wallace J (2010) Prophylactic mastectomy for the prevention of breast cancer. Cochrane Database Syst Rev (11):CD002748","DOI":"10.1002\/14651858.CD002748.pub3"},{"key":"4039_CR33","doi-asserted-by":"publisher","first-page":"2702","DOI":"10.1245\/s10434-010-1136-7","volume":"17","author":"JC Boughey","year":"2010","unstructured":"Boughey JC, Hoskin TL, Degnim AC et al (2010) Contralateral prophylactic mastectomy is associated with a survival advantage in high-risk women with a personal history of breast cancer. Ann Surg Oncol 17:2702\u20132709","journal-title":"Ann Surg Oncol"},{"key":"4039_CR34","unstructured":"Carson W, Otteson R, Hughes MA et al (2013) Contralateral prophylactic mastectomy for unilateral breast cancer: a review of the National Comprehensive Cancer Network (NCCN) database. In: Society of Surgical Oncology 66th annual cancer symposium abstract 13"},{"key":"4039_CR35","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1001\/jama.284.3.319","volume":"284","author":"MH Frost","year":"2000","unstructured":"Frost MH, Schaid DJ, Sellers TA et al (2000) Long-term satisfaction and psychological and social function following bilateral prophylactic mastectomy. JAMA 284:319\u2013324","journal-title":"JAMA"},{"key":"4039_CR36","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/S0960-9776(03)00136-X","volume":"12","author":"AN van Geel","year":"2003","unstructured":"van Geel AN (2003) Prophylactic mastectomy: the Rotterdam experience. Breast 12:357\u2013361","journal-title":"Breast"},{"key":"4039_CR37","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1007\/s10434-000-0150-6","volume":"7","author":"DK Payne","year":"2000","unstructured":"Payne DK, Biggs C, Tran KN et al (2000) Women\u2019s regrets after bilateral prophylactic mastectomy. Ann Surg Oncol 7:150\u2013154","journal-title":"Ann Surg Oncol"},{"key":"4039_CR38","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1001\/jama.2009.1568","volume":"302","author":"R Gartner","year":"2009","unstructured":"Gartner R, Jensen MB, Nielsen J et al (2009) Prevalence of and factors associated with persistent pain following breast cancer surgery. JAMA 302:1985\u20131992","journal-title":"JAMA"},{"key":"4039_CR39","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.breast.2010.05.003","volume":"19","author":"J Gahm","year":"2010","unstructured":"Gahm J, Wickman M, Brandberg Y (2010) Bilateral prophylactic mastectomy in women with inherited risk of breast cancer\u2014prevalence of pain and discomfort, impact on sexuality, quality of life and feelings of regret two years after surgery. Breast 19:462\u2013469","journal-title":"Breast"},{"key":"4039_CR40","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1093\/jnci\/81.24.1879","volume":"81","author":"MH Gail","year":"1989","unstructured":"Gail MH, Brinton LA, Byar DP et al (1989) Projecting individualized probabilities of developing breast cancer for White females who are being examined annually. J Natl Cancer Inst 81:1879\u20131886","journal-title":"J Natl Cancer Inst"},{"key":"4039_CR41","unstructured":"Breast Cancer Surveillance Consortium. Applied research program. National Cancer Institute. \n                    http:\/\/breastscreening.cancer.gov\/\n                    \n                  . Accessed 31 Dec 2014"},{"key":"4039_CR42","unstructured":"Surveillance, Epidemiology, and End Results (SEER) program: research data (1973\u20132010). National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch. \n                    www.seer.cancer.gov\n                    \n                  . Accessed 31 May 2016"},{"key":"4039_CR43","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.2214\/ajr.169.4.9308451","volume":"169","author":"R Ballard-Barbash","year":"1997","unstructured":"Ballard-Barbash R, Taplin SH, Yankaskas BC et al (1997) Breast Cancer Surveillance Consortium: a national mammography screening and outcomes database. Am J Roentgenol 169:1001\u20131008","journal-title":"Am J Roentgenol"},{"key":"4039_CR44","doi-asserted-by":"publisher","DOI":"10.1002\/0471722146","volume-title":"Applied logistic regression","author":"DW Hosmer","year":"2000","unstructured":"Hosmer DW, Lemeshow S (2000) Applied logistic regression, 2nd edn. Wiley, New York","edition":"2"},{"key":"4039_CR45","unstructured":"R Development Core Team (2016) R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna. \n                    https:\/\/www.R-project.org\/\n                    \n                  . Accessed 1 Jan 2016"},{"key":"4039_CR46","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1158\/1055-9965.EPI-12-1208-T","volume":"22","author":"N Houssami","year":"2013","unstructured":"Houssami N, Abraham LA, Kerlikowske K et al (2013) Risk factors for second screen-detected or interval breast cancers in women with a personal history of breast cancer participating in mammography screening. Cancer Epidemiol Biomark Prev 22:946\u2013961","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"4039_CR47","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1086\/301670","volume":"62","author":"G Parmigiani","year":"1998","unstructured":"Parmigiani G, Berry D, Aguilar O (1998) Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. Am J Hum Genet 62:145\u2013158","journal-title":"Am J Hum Genet"},{"key":"4039_CR48","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/s10549-013-2564-4","volume":"139","author":"S Biswas","year":"2013","unstructured":"Biswas S, Atienza P, Chipman J et al (2013) Simplifying clinical use of the genetic risk prediction model BRCAPRO. Breast Cancer Res Treat 139:571\u2013579","journal-title":"Breast Cancer Res Treat"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-016-4039-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10549-016-4039-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-016-4039-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,17]],"date-time":"2020-05-17T12:52:23Z","timestamp":1589719943000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10549-016-4039-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,4]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["4039"],"URL":"https:\/\/doi.org\/10.1007\/s10549-016-4039-x","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,4]]},"assertion":[{"value":"8 September 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}